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Neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE) is a life-threatening disorder and early diagnosis and
proper treatment are critical in the management of this neuropsychiatric manifestations in lupus. Brain magnetic resonance
imaging (MRI), electroencephalogram (EEG), neuropsychological tests, and lumbar puncture are clinical used for the diagnosis of
NPSLE. In addition to these tests, cytokine and chemokine levels in CSF have been reported as useful diagnostic marker of NPSLE.
Based on the number of recently published studies, this review overviewed the roles of cytokines and chemokines in NPSLE.
1.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease characterized by widespread immunologic abnormali-
ties and multiorgan involvement, including the skin, joints,
and kidney, as well as the peripheral and central nervous
systems (CNS). Neuropsychiatric syndromes of systemic
lupus erythematosus (NPSLE) may occur at any time during
the course of the disease, and symptoms are extremely
diverse, ranging from depression, psychosis, and seizures to
stroke [1]. The origin of minor clinical symptoms, such as
headaches and mood swings are not speciﬁc for NPSLE.
In fact, SLE patients may be under the inﬂuence of other
conditions capable of causing neuropsychiatric symptoms,
such as infections, severe hypertensions, metabolic com-
plications, steroid psychosis, and other drug toxicities [2].
Without proper treatment, neuropsychiatric involvement in
SLE is known to increase morbidity and mortality, and
therefore, the availability of beneﬁcial treatments increases
the need for the early recognition of neuropsychiatric
manifestations in lupus. Along with more speciﬁc diagnostic
tools and an eﬀective method of monitoring disease activity,
therapeutic responses are crucial in the management of
NPSLE. Currently, tests for diagnosing NPSLE include brain
magnetic resonance imaging (MRI), electroencephalogram
(EEG), neuropsychological tests, and lumbar puncture.
These ﬁndings are reported to be abnormal in some but not
all patients, and therefore, none of the ﬁndings are speciﬁc
for NPSLE. The large discrepancy in thereported frequency
of neuropsychiatric involvement in SLE patients (14%–75%)
further proves there is no single conﬁrmatory diagnostic
tool [3, 4]. Cytokines, small substances secreted by speciﬁc
cells of the immune system which carry signals locally
between cells, have important roles in the development
and functioning of both the innate and adaptive immune
response. Chemokines are chemoattractant cytokines which
play key roles in the accumulation of inﬂammatory cells at
thesiteofinﬂammation.Increasedlevelsofproinﬂammatory
cytokines and chemokines have been reported in the cerebral
spinal ﬂuids (CSF) of patients with NPSLE, and some
reports have shown cytokines such as interleukin-6 (IL-6),
IL-1, IL-8, IL-10, tumor necrosis factor (TNF)-α, interferon
(IFN)-γ, monocyte chemotactic protein 1 (MCP-1)/CCL2,
Interferon-gamma inducible protein-10 (IP-10)/CXCL10
andFractalkine/CX3CL1 tobeelevatedintrathecally,thereby
allowing these cytokines to be used as diagnostic tools [5–9].
Cytokines and chemokines are considered to be ther-
apeutic targets in several chronic inﬂammatory disorders2 Journal of Biomedicine and Biotechnology
such as SLE. Based on the number of recently published
studies, this review focuses on the cytokines and chemokines
as biomarkers as well as pathogenic factors in NPSLE.
2. Cytokines
The role of TNF-α in lupus is still controversial. TNF-α may
be protective in patients with lupus, since low TNF-α activity
is associated with increased disease activity. In some patients
with rheumatoid arthritis who were treated with anti- TNF-
α antibodies, antidouble-stranded DNA antibodies were
detected and lupus developed in a few of these patients. By
contrast, TNF-α may promote the pathogenesis of lupus,
since the level of TNF-α messenger RNA was high in kidney-
biopsy specimens from patients with lupus nephritis and
there is a report showing that giving the anti- TNF-α
antibody agent, inﬂiximab, to six patients with lupus led to
resolution of joint swelling in three patients with arthritis
and a 60% reduction of urinary protein loss in four patients
with renal lupus [10, 11]. Serum levels of interleukin-10 (IL-
10) are consistently high in patients with lupus, and they
correlate with the activity of the disease. IL-10 has a number
of biologic eﬀects, including stimulation of polyclonal popu-
lationsofBlymphocytes.Blockingthiscytokinecouldreduce
the production of pathogenic autoantibodies [11]. Serum
levels of interferon-α (IFN-α) are also elevated in patients
with active lupus and microarray studies showed that 13
genesregulatedbyIFNwereupregulatedinperipheral-blood
mononuclear cells from patients with lupus, as compared
with healthy controls [11].
Several cytokines such as IL-4, IL-6, IL-8, IL-10, TNF-α,
IFN-α,a n dI F N - γ have been reported to be elevated in the
cerebrospinal ﬂuid (CSF) from patients with NPSLE.
2.1. As Biomarkers. Among reported cytokines, IL-6 has
been shown to have the strongest positive association with
NPSLE. IL-6 level in the CSF of NPSLE was reported to
be elevated without damage of the blood-brain barrier. In
addition, the expression of IL-6 mRNA was elevated in
the hippocampus and cerebral cortex, suggesting that IL-6
expression was increased within the entire CNS of NPSLE
[16,17].ThereisareportstudyingtheexpressionofIL-4,IL-
10 TNF-α,a n dI F N - γ in both peripheral blood lymphocytes
(PBLs) and CSF from NPSLE patients whereby the authors
found that mRNA for IL-10, TNF-a, and IFN-g were
increased in PBLs while only IL-10 and IFN-γ were elevated
inCSF[6].Anexhaustivestudyofcytokinesandchemokines
recently reported that IL-6 and IL-8 were elevated in NPSLE
compared with non-NPSLE and nonautoimmune disease
patients. This study also found that IL-2, IL-4, IL-10, TNF-α,
and IFN-γ were low in all groups examined [21]. In other
reports, no association was found between IL-2, IL-6, IL-
10, TNF-α,a n dI F N - γ with NPSLE [13, 14]. A recent study
has shown that the sensitivity and speciﬁcity of CSF IL-
6 for diagnosis of lupus psychosis was 87.5% and 92.3%,
respectively, indicating that CSF IL-6 might be an eﬀective
marker for the diagnosis of lupus psychosis [26]. The TNF
family ligands BAFF (B-cell activating factor of TNF family)
and APRIL (a proliferation-inducing ligand) are essential for
B-cell survival and function. Elevated serum levels of BAFF
and APRIL have been reported in patients with systemic
lupus erythematosus (SLE). Recently BAFF and APRIL were
studied in CSF of NPSLE patients. They found that levels of
APRIL in CSF were more than 20-fold higher and levels of
BAFF in CSF that were more than 200-fold higher than those
of healthy controls. Comparing the levels of APRIL in CSF
between NPSLE and non-NPSLE patients, enhanced levels
of APRIL were noted in NPSLE. Moreover, they found that
CSF levels of APRIL correlated with BAFF but not with IL-
6[ 27]. There is a report regarding the association between
cytokine levels and acute confusional state (ACS) of NPSLE.
The authors performed a prospective study using a cohort of
59 patients with SLE and compared those with and without
ACS as well as associations between ACS and each CSF test
[IL-6, IL-8, IFN-α, IgG index, and Q-albumin]. In this study,
ACS was diagnosed in 10 patients (ACS group), SLE-related
CNS syndromes except ACS in 13, and no CNS syndromes in
36 (non-CNS group). CSF IL-6 levels in the ACS group were
signiﬁcantly higher than those in the non-CNS group (P<
.05) and a positive IgG index (P = .028) was signiﬁcantly
associated with ACS. No other test showed a signiﬁcant
association with ACS. The positive and negative predictive
values for the diagnosis of ACS in SLE were 80% and 85%
for elevated CSF IL-6 levels (> or = 31.8pg/mL), and 75%
and 83% for the IgG index, respectively. From these results,
the authors concluded that no single CSF test had suﬃcient
predictive value to diagnose ACS in SLE, although CSF IL-6
levels and the IgG index showed statistical associations with
ACS [28].
A summary of the reported results is shown in Table 1.
2.2. As Pathogenic Factors. Although some cytokines are
important biomarkers of NPSLE, the mechanism for the
elevated levels ofcytokines is thus far unknown. As SLE is an
autoimmune disorder characterized by numerous autoanti-
bodies, a pathogenetic role for autoantibodies is theoretically
suspected. Immune complexes in SLE can stimulate IFN-α
andthereisstrongevidenceinhumansandinmicethatIFN-
α can cause neuropsychiatric manifestations. Santer DM et
al. used a bioassay containing plasmacytoid dendritic cells to
demonstrate that NPSLE CSF induced signiﬁcantly higher
IFN-α compared with CSF from patients with multiple
sclerosis or other autoimmune disease controls. When
normalized for IgG concentration, NPSLE CSF was 800-
fold more potent at inducing IFN-α compared with paired
serum due to inhibitors present in serum. In addition to
IFN-α, immune complexes formed by CSF autoantibodies
produced signiﬁcantly increased levels of IP-10/CXCL, IL-
8, and MCP-1. From these results they proposed a two-
step model of NPSLE whereby CSF autoantibodies bind to
antigensreleasedbyneurocytotoxicantibodiesorotherbrain
cell injury, and the resulting immune complexes stimulate
IFN-αandproinﬂammatorycytokinesandchemokines[22].
Recently, our group has shown that IgG anti-NR2 glutamate
receptor antibodies (anti-NR2) from SLE patients directly
activated endothelial cells by the activation of NF-κB signal-
ing, resulting in the upregulation of adhesion molecules andJournal of Biomedicine and Biotechnology 3
Table 1: Cytokines in CSF of NPSLE.
Cytokines NPSLE Control group Authors Year
IL-1 Incresed None Alcocer-Varela et al. [12] 1992
IL-1β Same Neulogical symptoms without neurological diseases Gilad et al. [13] 1997
soluble IL-2R Incresed Neulogical symptoms without neurological diseases Gilad et al. [13] 1997
IL-6
Incresed Non-NPSLE, HI J¨ onsen et al. [14] 2003
Incresed HI, neurocysticerosis Jara et al. [15] 1998
Incresed Non-NPSLE Hirohata and Miyamoto [16] 1990
Incresed Cerebral infarction Hirohata and Hayakawa [17] 1999
Incresed None Alcocer-Varela et al. [12] 1992
Incresed CNS inﬂammation, non-inﬂammatory CNS diseases Tsai et al. [18] 1994
Incresed Non-NPSLE Trysberg et al. [19] 2009
Incresed HI Dellalibera et al. [20] 2003
Incresed Non-NPSLE, SM, non-AID Fragoso-Loyo [21] 2007
IL-8
Incresed Non-NPSLE Trysberg et al. [19] 2009
Incresed Non-NPSLE, SM, non-AID Fragoso-Loyo [21] 2007
Incresed MS, other AID Santer et al. [22] 2009
IL-10
Same Non-NPSLE, HI J¨ onsen et al. [14] 2003
Incresed HI Dellalibera et al. [20] 2003
Same Non-NPSLE, SM, non-AID Fragoso-Loyo [21] 2007
TNF-α
Incresed HI Dellalibera et al. [20] 2003
Same Non-NPSLE, SM, non-AID Fragoso et al. [21] 2007
Same Neulogical symptoms without neurological diseases Gilad et al. [23] 1997
IFN-γ Same Non-NPSLE, SM, non-AID Fragoso-Loyo et al. [21] 2007
IFN-α
Incresed Non-NPSLE, HI J¨ onsen et al. [14] 2003
Incresed Non-NPSLE Winﬁeld et al. [24] 1983
Incresed Non-NPSLE Shiozawa et al. [25] 1992
AID: autoimmune diseases, HI: healthy individuals, MS: multiple sclerosis, SM: septic meningitis.
cytokine production [29]. Further immunological studies
are expected to show how autoantibodies in SLE patients
work to promote the cytokine storm associated with the
pathophysiology of NPSLE.
3. Chemokines
Chemokines in humans comprise more than 50 small (8-
to-10-kDa) heparin-binding proteins with 20 to 70 percent
homology in amino acid sequences. Chemokines were
originally identiﬁed by their chemotactic activity on bone
marrow-derived cells [30, 31]. They are classiﬁed into at
least four families according to the location of their cysteine
residues. The four chemokine groups are CC, C, CXC,
and CX3C, where C is a cysteine and X any amino-acid
residue, and their receptors are consequently classiﬁed as
CCR, CR, CXCR, and CX3CR. The chemokine receptors are
bound to the cell membrane through seven transmembrane
helical segments coupled with a G-protein which transduces
the intracellular signal. The two major subclasses include
the CC chemokines where the cysteines are neighboring
and the CXC chemokines where the cysteines are separated
by one amino acid. The CXC chemokines mainly act on
neutrophils and lymphocytes, whereas the CC chemokines
mainly act on monocytes and lymphocytes without aﬀecting
neutrophils [32]. Lymphotactin, in the C chemokine family,
is similar to members of both the CC and CXC chemokine
families but lacks two of the four cysteine residues and
is a potent attractant for T cells, but not for monocytes
or neutrophils [33]. Fractalkine, in the CX3C family, is a
cell-surface-bound protein, in which the ﬁrst two cysteine
residues are separated by three amino acids. Fractalkine
has potent chemoattractant activity for T cells and mono-
cytes [34]. One characteristic feature of chemokines is the
redundancy of the system. Several chemokines bind to
more than one receptor and the majority of chemokine
receptors have multiple ligands leading to the generation
of multiple pathways directing similar cellular responses.
Until recently, chemokines have been named randomly, with
no clear system being used. Some have been included in
the same group as\interleukins (e.g., IL-8), while others
have been given names describing a function, for example,
macrophage chemoattractant proteins. In an attempt to
clarify the confused and complex nomenclature associated
withchemokines,thenomenclatureofthechemokinesystem
has been revised. The name referring to a speciﬁc biologic
function has been replaced by the chemokine subfamily
name followed by a number (e.g., MCP-1 is CCL2) [35, 36].
In this review, chemokines are described with common4 Journal of Biomedicine and Biotechnology
Table 2: Chemokines and chemokine receptors in NPSLE.
Chemokines Chemokine receptors Cell Types
IL-8/CXCL8 CXCR1 Neutrophils, monocytes
IP-10/CXCL10 CXCR3 Th1 cells, mast cells, mesangial cells
fractalkine/CXCL1 CX3CR1d Macrophages, endothlial cells, smooth muscle cells
RANTES/CCL5 CCR1 Tcells, monocytes, eosinophils, basophils
RANTES/CCL5 CCR3 Eosinophils, basophils, mast cells, Th2 cells
MCP-1/CCL2 CCR2 Memory T cells, monocytes, immature dendritic cells
names as well as the revised names according to the new
nomenclature. Several chemokines such as IL-8/CXCL8, IP-
10/CXCL10, fractalkine/CXCL1, RANTES/CCL5, and MCP-
1/CCL2 have been reported to be elevated in the CSF from
patients with NPSLE (Table 2).
3.1. As Biomarkers
3.1.1. CC Chemokines. Monocyte chemoattractant protein
(MCP)-1/CCL2 (a ligand of CCR2) can attract monocytes, T
cells, NK cells, and basophils [7, 37]. It is a high-aﬃnity lig-
and for the CCR2 chemokine receptor, that is, constitutively
expressed in monocytes but is expressed on lymphocytes
only after stimultion by IL-2. Expression of CCR2 on
monocytes can be downregulated by lipopolysaccharides.
We and others have reported that CSF MCP-1/CCL2 levels
are higher in NPSLE patients than in non-NPSLE patients
[7, 21]. In addition, we reported that levels of MCP-1/CCL2
decreasedafterimmunosuppressivetreatment.Furthermore,
we compared the levels of MCP-1/CCL2 among various neu-
ropsychiatric symptoms. However, as some patient groups
h a v ev e r yf e wc a s e s ,w ew e r eu n a b l et oc o n c l u d ew h i c ht y p e
of symptom was associated with the increase of CSF MCP-
1/CCL2 levels in our study [7].
(RANTES)/CCL5 (a ligand of CCR1, CCR3, and CCR5)
is another CC chemokine which attracts monocytes, mem-
ory T cells and NK cells and is implicated in the patho-
physiology of SLE, rheumatoid arthritis (RA), and mul-
tiple sclerosis (MS) [38]. Chemokine receptor CCR5 is
preferentially expressed on Th1 lymphocytes and has been
reported to have an important role in the pathogenesis
of RA. It has been reported that systemic administration
of a small molecular weight antagonist of CCR5, SCH-X,
suppressed the development of collagen-induced arthritis
(CIA) in a monkey model of RA [39]. We also provided
evidence showing that systemic administration of TAK-779,
a nonpeptide compound with a small molecular weight,
inhibits the development of adjuvant-induced arthritis in
rats [40]. Recent reports suggest that CSF levels of CCL5
are increased in NPSLE patients compared with non-NPSLE
patients [21].
3.1.2. CXC Chemokines. IL-8/CXCL8 (a ligand of CXCR1
and CXCR2) was the ﬁrst chemokine identiﬁed to be
involved in leukocyte chemotaxis such as polymorphonu-
clear neutrophils and speciﬁc T cells [41, 42]. There are
several reports showing that IL-8/CXCL8 levels in CSF are
elevated in NPSLE [21, 43].
Interferon-gammainducibleprotein-10(IP-10)/CXCL10
(a ligand of CXCR3) is expressed and secreted by monocytes
and ﬁbroblasts following stimulation with IFN-γ [29, 44].
IP-10/CXCL10 is a high-aﬃnity ligand for the CXCR3
chemokine receptor which is mainly expressed on helper
T1 (Th1) cells. The predominance of Th1 versus Th2 cells
in NPSLE patients remains unresolved. We and others have
reported that IP-10/CXCL10 was upregulated in the CNS
ﬂuid of NPSLE [9, 21].
3.1.3. C and CX3C Chemokines. The C chemokine family
is represented by two chemokines, lymphotactin/XCL1,
and SCM-1β/XCL2, whereas the CX3C chemokine family
contains only one member, called fractalkine/CX3CL1 [47].
Fractalkine/CX3CL1 is synthesized by endothelial cells as
a type 1 transmembrane protein which is then cleaved by
proteolysis, possibly mediated by TNF-α-converting enzyme
(TACE) and ADAM 10, thereby yielding the soluble form
of Fractalkine/CX3CL1 (sFKN). Fractalkine/CX3CL1 binds
to a receptor known as CXCR1 signaling via the G protein
pathway in NK cells, macrophages and a certain proportion
of T cells. Fractalkine/CX3CL1 plays important roles in the
pathogenesisofRAbyattractingproinﬂammatorycells,such
as activated macrophages and T cells [48]. There is a report
showing that levels of sFKN/s CX3CL1 were elevated in the
CSF of NPSLE. In this report, both serum and CSF sFKN/s
CX3CL1 levels declined with treatment [45]. However, our
group did not ﬁnd a signiﬁcant increase of sFKN/s CX3CL1
in CSF from NPSLE patients compared with that of non-
NPSLE patients [46].
3.1.4. Ratio of Two Diﬀerent Chemokine Levels. We reported
that the IP-10/MCP-1 ratio is a useful marker to detect
NPSLE [8]. In our study, the IP-10/MCP-1 ratio in the
NPSLE group was signiﬁcantly higher than that in the non-
NPSLE group (P = .0000014, Mann-Whitney’s U test).
The discriminative ability (area under the curve) of each
chemokine was 0.63111 (95% conﬁdence interval [95% CI]
822.4064–7787.1975) (IP-10/CXCL10), 0.67626 ([95% CI]
418.6142–1761.8262) (MCP-1/CCL2), and 0.82672 ([95%
CI] 1.222729–5.011448) (IP-10/MCP-1 ratio). There was no
correlation between the levels of MCP-1 in CSF and that in
serum (r =− 1332, P = .2481) and the levels of IP-10 in
CSF and that in serum (r =− 1445, P = .3842). There wasJournal of Biomedicine and Biotechnology 5
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Table 3: CHemokines in CSF of NPSLE.
Chemokines NPSLE Control group Authors Year
MCP-1/CCL2 Increased Non-NPSLE Iikuni et al. [7] 2006
Increased Non-NPSLE Fragoso-Loyo [21] 2007
RANTES/CCL5 Increased Non-NPSLE Fragoso-Loyo [21] 2007
IL-8/CXCL8
Increased Non-NPSLE Trysberg et al. [43] 2003
Increased Non-NPSLE, SM, non-AID Fragoso-Loyo [21] 2007
Increased MS, other AID Santer et al. [22] 2009
IP-10/CXCL10 Increased Non-NPSLE Okamoto et al. [9] 2004
Fractalkine Increased Non-NPSLE Yajima et al. [45] 2005
Same Non-NPSLE Sato et al. [46] 2006
IP-10/MCP-1 ratio Increased Non-NPSLE Okamoto et al. [8] 2006
AID: autoimmune diseases, MS: multiple sclerosis, SM: septic meningitis.
also no correlation between the levels of MCP-1 and IL-6
(r =− 0.1229, P = .462), IL-8 (r =− 0.1585, P = .349),
and IFN alpha (r =− 0.0818, P = .179), and between IP-
10 and IL-6 (r =− 0.1435, P = .384), IL-8 (r =− 0.1553,
P = .332), and IFN alpha (r =− 0.1021, P = .213). We
concluded that CSF IP-10/MCP-1 ratios are higher in NPSLE
patients than in non-NPSLE patients and that this index is a
useful diagnostic marker of NPSLE [8].
The summary of the reported results are shown in
Table 3.
3.2. As Pathogenic Factors. There is growing evidence show-
ing that chemokines not only recruit speciﬁc subsets of
lymphocytes and inﬂammatory cells but also determine the
type of immune response at the site of inﬂammation and
that chemokines have pivotal roles in the development and
progression of autoimmune disorders.
In the course of an immune response, distinct subsets
of eﬀecter T cells and regulatory T cells are generated
in the lymphoid compartments after the diﬀerentiation of
naive T cells under the inﬂuence of speciﬁc cytokines.6 Journal of Biomedicine and Biotechnology
Chemokines guide these T-cell subsets out of the lymphoid
compartment and into sites of inﬂammation and infection.
Before the commitment of antigen-speciﬁc T-cell subsets,
innate T cells such as NKT and γδ T cells work as the
ﬁrst line of host defence and also are guided to the sites
of inﬂammation by chemokines. Naive T cells diﬀerentiate
into Th1 cells under the direction of the cytokine IL-12 and
transcription factor T-bet. Th1 cells are characterized by the
productionofIFN-γ andhavearoleintheprotectionagainst
intracellular pathogens. On the other hand, IL-4 and the
transcription factor GATA-3 are critical in the diﬀerentiation
of naive T cells into Th2 cells. Th2 cells are characterized
by the production of IL-4, IL-5, and IL-13 which mediate
protection against parasites and allergic responses. Th1 cells
preferentially express CCR5, CXCR3, and CXCR6, whereas
Th2 cells preferentially express CCR4 and CCR8.
We reported that CSF MCP-1/CCL2 and IP-10/CXCL10
levels are higher in NPSLE patients than in non-NPSLE
patients, indicating possible involvement of this chemokine
in the pathogenesis of NPSLE. The receptor of IP-
10/CXCL10, CXCR3 is predominantly expressed on natural
killer cells and activated T cells, especially Th1 cells. On the
other hand, the receptor of MCP-1/CCL2, CCR2 is expressed
not only on activated T cells and natural killer cells but also
on monocytes, basophils, and dendritic cells. CD4+ T cells
populations that upregulate expression of the transcription
factor RORgt can diﬀerentiated into IL-17 producing CD4+
T cells (Th17 cells) that diﬀer in phenotype and function
from Th1 and Th2 cells. Th17 cells are thought to protect
against bacteria and fungi and these cells are also involved in
the pathogenesis of autoimmne diseases [44]. Interestingly,
CCR2 is expressed on a subpopulation of Th17 cells which
produce a large amount of IL-17 but little IFN-γ [49]. These
resultsimplicatethediﬀerentialcontributionofbothCXCR3
and CCR2 signaling in the pathogenesis of NPSLE, especially
on eﬀector T cells such as Th1, Th2, and Th17 cells.
4. Conclusion
Although a large number of studies have been performed,
the precise pathophysiology of NPSLE is not completely
understood. As we presented here, various cytokines and
chemokines are highly expressed in the brain of NPSLE
patients, and it is believed that these small molecules have
important roles in the pathogenesis of NPSLE. However, the
molecularmechanismsbywhichthesemoleculesworkinthe
course of the development of NPSLE have not yet been com-
pletely revealed. Cytokines and chemokines are expressed
by the stimulation of NF-κB signaling and signal trans-
duction pathways involving other trancription factors [50].
As mentioned above, our group has shown that IgG anti-
NR2 glutamate receptor antibodies (anti-NR2) from SLE
patients direct NF-κB signaling in endothelial cells, resulting
in the upregulation of adhesion molecules and cytokine
production. Therefore, autoantibodies which are character-
istic features of SLE bind to corresponding autoantigens
on the cell surface and these interactions may stimulate
signaling cascades, resulting in the activation of certain
transcription factors (Figure 1). This activation of signal
transduction pathways involving these transcription factors
might activate transcription and expression of cytokines
and chemokines, resulting in a cytokines/chemokines storm
and the development of NPSLE pathophysiology. Further
molecular studies are required to prove this proposed
mode of action for cytokines and chemokines. In addition,
cytokines and chemokines are considered to be therapeutic
targets in NPSLE. As most of the cytokines and chemokines
involved inNPSLEhavepleiotrophic rolesinotherbiological
processes, inhibition of these cytokines and chemokines
might invite unexpected side eﬀects in vivo.C o o p e r a t i v e
contributionofbothclinicalstudiesandmolecularbiological
studies is required for the development of ideal therapeutic
strategies against NPSLE.
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